Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation

H. Schmidt, H. Einsele, K. Jaschonek, R. Dopfer, G. Ehninger, Arnold Glazier, Gary C. Yee, H. Joachim Deeg

Research output: Contribution to journalLetterpeer-review

3 Scopus citations


To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.

Original languageEnglish (US)
Pages (from-to)1607-1608
Number of pages2
JournalNew England Journal of Medicine
Issue number24
StatePublished - Dec 15 1988
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Cyclosporine and Graft-versus-Host Disease after Bone Marrow Transplantation'. Together they form a unique fingerprint.

Cite this